after joining, undergo a series of medical examinations that include blood tests, imaging studies, and evaluation of disease status.

the purpose is to record the condition before any study medication is given.

the participant is allocated to receive either mk-1045 (test drug) or blinatumomab (comparator) according to the study randomization schedule.

if assigned to mk-1045, an intravenous infusion of a solution for infusion is given. the specified dose is 0 % (v/v), which indicates the concentration of the preparation.

if assigned to blinatumomab, an intravenous infusion is given at a dose of 28 µg per administration. the medication is supplied in the form identified as phf00230mig.

the infusion is performed according to the schedule defined for each treatment cycle.

the participant receives the assigned infusion in each of the first three treatment cycles.

after each cycle, clinical evaluations are performed to assess response of the leukemia and to monitor safety.

the primary goal during these cycles is to achieve complete remission, defined as the disappearance of detectable disease.

blood and bone‑marrow samples are examined to determine whether complete remission or minimal residual disease negativity has been reached.

any adverse events (undesired medical occurrences) are recorded, and the severity is evaluated.

if an adverse event is judged serious, the study medication may be stopped according to protocol.

if the participant tolerates the medication and no criteria for stopping are met, treatment may continue beyond the first three cycles as outlined in the study plan.

if a serious adverse event occurs or if the participant chooses to stop, the study medication is discontinued and follow‑up assessments continue.

after the treatment phase, the participant is monitored over time to record overall survival, which measures the length of time the participant remains alive after starting the study.

follow‑up visits may include clinical examinations and laboratory tests as defined by the protocol.